Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMS vs LH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

LH Overall Winner 6-Pillar Tally: AMS 1 – 5 LH Matrix Metrics: AMS 1 – 9 LH

As of Nov 16, 2026, Labcorp Holdings Inc. (LH) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas LH carries 40.8/100 (SELL) at $372.46 (19.0x Forward P/E, 11.2% operating margin).

  • Defensive Composite Rating Caution: Although LH compares more favorably head-to-head, both AMS (33.8/100 SELL) and LH (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile LH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 70.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMS vs LH
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32
LH NYSE Head-to-Head Winner
Labcorp Holdings Inc.
Services-Medical Laboratories
$372.46
+0.53% 1D
Market Cap $30.1B
TTM Revenue $14.6B
Forward P/E 19.0x
Beta / 30D Vol 0.37β · 36% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 17.0 Fund 35.0 Flow 58.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 71
RSI-14: 70.5 · SMA20: $354.70 · SMA50: $330.55

6-Pillar Scorecard Institutional Category Breakdown (AMS 1 – 5 LH)

Columns: Metric · AMS · LH
1. Valuation Multiples LH
Forward P/E 44.6x 19.0x
Trailing P/E 44.6x 30.4x
PEG Ratio N/M 1.64x
EV / Revenue 0.8x 2.5x
2. Growth & Scale LH
Revenue Growth (YoY) +19.2% +6.9%
Earnings Growth (YoY) -38.1% +3.2%
TTM Revenue (USD) $30M $14.6B
Market Cap $7.2M $30.1B
3. Profitability & Quality LH
Gross Margin 34.8% 29.0%
Operating Margin -7.4% 11.2%
Net Profit Margin -5.8% 6.9%
Return on Equity (ROE) -12.1% 11.4%
4. Balance Sheet & Cash Flow LH
Cash Generation (TTM) -$916,000 $1.29B
Cash Flow Margin -3.0% 8.8%
Net Cash / Leverage $17M Net Debt (0.95x D/E) $6.51B Net Debt (0.77x D/E)
Dividend Yield None (0.00%) 0.77%
5. Options & Positioning LH
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 24.6% (16th %ile)
Put/Call OI Skew N/A 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 42.2% of Rev ($13M) 17.8% of Rev ($2.60B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMS (1) vs LH (9)
Institutional Metric AMS LH Criterion Row Edge
Market Capitalization
Scale
$7.2M $30.1B Larger Scale LH
Trailing P/E Ratio
Valuation
44.6x 30.4x Lower Multiple LH
Forward P/E Ratio
Valuation
44.6x 19.0x Lower Multiple LH
Revenue Growth (YoY)
Growth
+19.2% +6.9% Higher Growth AMS
Operating Margin (TTM)
Profitability
-7.4% 11.2% Higher Margin LH
Net Profit Margin
Profitability
-5.8% 6.9% Higher Margin LH
Return on Equity (ROE)
Capital Efficiency
-12.1% 11.4% Higher ROE LH
52-Week Range Position
Momentum
6% ($1–$2) 98% ($245–$375) Stronger Trend LH
Beta / 30D Volatility
Risk Regime
0.18β · 46% Vol 0.37β · 36% Vol Lower Realized Risk LH
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 40.8 / 100 (SELL) Higher Composite LH
Trailing 12M Revenue (USD)
Operating Scale
$30M $14.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.8% 29.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev 1.64x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$916,000 ($17M Net Debt (0.95x D/E)) $1.29B ($6.51B Net Debt (0.77x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LH +33.55 pp
AMS: -16.41% · LH: +17.14%
3M Horizon LH +44.75 pp
AMS: -29.14% · LH: +15.61%
6M Horizon LH +69.31 pp
AMS: -23.57% · LH: +45.74%
1Y Horizon LH +91.28 pp
AMS: -52.23% · LH: +39.05%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMS Revenue LH Revenue AMS Op. Margin LH Op. Margin Margin Leader
FY2018 $20M $11.3B 9.4% 11.7% LH
FY2019 $20M $11.6B 7.5% 11.5% LH
FY2020 $20M $14.0B -53.1% 17.5% LH
FY2021 $20M $13.1B 7.7% 23.2% LH
FY2022 $20M $11.9B 12.3% 12.1% AMS
FY2023 $20M $12.2B 1.3% 6.0% LH
FY2024 $30M $13.0B -9.9% 8.4% LH
FY2025 $30M $13.9B -12.8% 9.9% LH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LH CONSOLIDATION
59d in phase · OBV ACCUMULATION
Current IV 24.6%
IV Percentile 16th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology
LH Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $30.1B market capitalization and 11.2% operating margin.
OpEx & R&D Reinvestment 17.8% of Rev ($2.60B)
90D Engineering Disclosures 0 Published

Investor FAQ AMS vs LH Key Questions & Quantitative Answers

As of Nov 16, 2026, Labcorp Holdings Inc. (LH) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMS carries a Unified Composite Score of 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin), whereas LH carries 40.8/100 (SELL) at $372.46 (19.0x Forward P/E, 11.2% operating margin). Defensive Composite Rating Caution: Although LH compares more favorably head-to-head, both AMS (33.8/100 SELL) and LH (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile LH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 70.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LH leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with LH at +6.9% YoY revenue growth and +3.2% YoY earnings growth on $14.6B TTM revenue (29.0% gross margin, 11.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMS cumulative revenue shifted +50.0% while LH shifted +23.1%. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus 17.8% of Rev ($2.60B) (0 disclosures) for LH.

LH screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas LH trades at 19.0x Forward P/E, 30.4x Trailing P/E, 1.64x PEG, and 2.5x EV/Revenue (8.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus LH (11.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, LH carries 24.6% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.37β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.